Real-world effectiveness and safety of dupilumab in children with atopic dermatitis: a Latin American single-center study

Abstract

In this Latin American pediatric cohort, dupilumab achieved marked and sustained improvements in disease severity and quality of life, with a favorable safety profile. This real-world study addresses a regional evidence gap and supports dupilumab as an effective and well-tolerated treatment for moderate-to-severe pediatric AD.